Divi's Laboratories 향후 성장
Future 기준 점검 3/6
Divi's Laboratories (는) 각각 연간 19.5% 및 16.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.6% 로 예상됩니다.
핵심 정보
19.5%
이익 성장률
19.40%
EPS 성장률
| Life Sciences 이익 성장 | 25.9% |
| 매출 성장률 | 16.1% |
| 향후 자기자본이익률 | 18.62% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 23 May 2026 |
최근 향후 성장 업데이트
분석 기사 • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...분석 기사 • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...분석 기사 • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...Recent updates
내러티브 업데이트 • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.
내러티브 업데이트 • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).내러티브 업데이트 • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
내러티브 업데이트 • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).내러티브 업데이트 • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).내러티브 업데이트 • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).분석 기사 • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...내러티브 업데이트 • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).내러티브 업데이트 • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).분석 기사 • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).분석 기사 • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...분석 기사 • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...내러티브 업데이트 • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.분석 기사 • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...내러티브 업데이트 • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.분석 기사 • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...분석 기사 • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...분석 기사 • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...
새로운 내러티브 • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 3/31/2028 | 146,592 | 37,794 | 17,228 | N/A | 28 |
| 3/31/2027 | 124,049 | 30,913 | 12,582 | N/A | 29 |
| 3/31/2026 | 106,459 | 25,584 | 9,507 | N/A | 30 |
| 12/31/2025 | 103,140 | 24,790 | N/A | N/A | N/A |
| 9/30/2025 | 100,290 | 24,850 | 540 | 23,720 | N/A |
| 6/30/2025 | 96,520 | 23,060 | N/A | N/A | N/A |
| 3/31/2025 | 93,600 | 21,910 | 2,150 | 16,530 | N/A |
| 12/31/2024 | 90,780 | 20,670 | N/A | N/A | N/A |
| 9/30/2024 | 86,140 | 18,360 | 4,750 | 16,480 | N/A |
| 6/30/2024 | 81,850 | 16,740 | N/A | N/A | N/A |
| 3/31/2024 | 78,450 | 16,000 | 2,580 | 12,610 | N/A |
| 12/31/2023 | 74,926 | 13,834 | N/A | N/A | N/A |
| 9/30/2023 | 73,456 | 13,314 | 7,927 | 15,127 | N/A |
| 6/30/2023 | 72,906 | 14,774 | N/A | N/A | N/A |
| 3/31/2023 | 77,670 | 18,240 | 19,860 | 24,590 | N/A |
| 12/31/2022 | 83,353 | 23,971 | N/A | N/A | N/A |
| 9/30/2022 | 91,208 | 29,925 | 22,153 | 28,404 | N/A |
| 6/30/2022 | 92,538 | 31,054 | N/A | N/A | N/A |
| 3/31/2022 | 89,599 | 29,605 | 11,986 | 19,118 | N/A |
| 12/31/2021 | 82,297 | 25,678 | N/A | N/A | N/A |
| 9/30/2021 | 74,379 | 21,362 | 4,760 | 13,465 | N/A |
| 6/30/2021 | 71,996 | 20,493 | N/A | N/A | N/A |
| 3/31/2021 | 69,695 | 19,843 | 10,367 | 19,469 | N/A |
| 12/31/2020 | 65,710 | 18,705 | N/A | N/A | N/A |
| 9/30/2020 | 62,658 | 17,590 | 10,714 | 20,167 | N/A |
| 6/30/2020 | 59,620 | 15,962 | N/A | N/A | N/A |
| 3/31/2020 | 53,945 | 13,765 | 327 | 12,159 | N/A |
| 12/31/2019 | 52,719 | 12,803 | N/A | N/A | N/A |
| 9/30/2019 | 52,356 | 13,106 | N/A | 7,962 | N/A |
| 6/30/2019 | 51,139 | 13,575 | N/A | N/A | N/A |
| 3/31/2019 | 49,463 | 13,527 | N/A | 9,543 | N/A |
| 3/31/2018 | 38,915 | 8,770 | N/A | 7,759 | N/A |
| 3/31/2017 | 40,643 | 10,604 | N/A | 11,504 | N/A |
| 3/31/2016 | 37,764 | 11,258 | N/A | 10,379 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: DIVISLAB 의 연간 예상 수익 증가율(19.5%)이 saving rate(6.9%)보다 높습니다.
수익 vs 시장: DIVISLAB 의 연간 수익(19.5%)이 Indian 시장(16.2%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: DIVISLAB 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: DIVISLAB 의 수익(연간 16.1%)이 Indian 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: DIVISLAB 의 수익(연간 16.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: DIVISLAB의 자본 수익률은 3년 후 18.6%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/23 16:20 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Divi's Laboratories Limited는 46명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Antique Stockbroking Ltd. |